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56613 EVALUATION OF THE EFFECT OF SUPPRESSIVE DOSE OF LEVOTHYROXINE ON BONE MASS IN 
CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH DIFFERENTIATED THYROID CARCINOMA
André Borsatto Zanella1, Rafael Selbach Scheffel1, José Miguel Dora1, Tayane Muniz Fighera1, Poli Mara Spritzer1, Ana Luiza 
Silva Maia1,
1 Universidade Federal do Rio Grande do Sul (UFRGS)
Introduction: Levothyroxine (LT4) suppressive therapy (sLT4) is a cornerstone of treatment for children and adolescents with 
differentiated thyroid carcinoma (DTC). Nevertheless, the impact of supraphysiological doses of thyroid hormone in young 
patients before peak bone mass has been poorly studied. Objective: To evaluate the effect of TSH suppression on bone mass 
in a population of children, adolescents and young adults with DTC. Methods: Patients with diagnosis of DTC on long-term 
sT4 who initiated this therapy before 25 years of age were selected and compared to thyroidectomized patients under LT4 phy-
siological replacement matched by sex, age and body mass index (BMI). The clinical variables were extracted from a Thyroid 
Outpatient Clinic cohort database. All patients were 19 years of age or older and underwent a dual-energy X-ray absorptiome-
try (DXA) to determine the bone mineral density (BMD) at lumbar and hip. Results: Thirty patients (96.6% papillary subtype, 
76.7% females) under sLT4 therapy and 11 thyroidectomized individuals under LT4 replacement therapy (8 patients with me-
dullary thyroid carcinoma and 3 with multinodular goiter; 72.7% of females) were included. There were no differences on age 
(27.8 ± 5.7 vs. 28.4 ± 7.1 years, P = 0.8), female/male ratio (8/3 vs. 8/3, P = 1.0) and BMI (24.0 ± 4.3 vs. 26.5 ± 3.4 kg/m2, P = 0.1) 
between the groups. The dose of levothyroxine per kilogram (kg) of body weight was 2.4 ± 0.7 mcg/kg and 1.8 ± 0.3 mcg/kg 
in sLT4 and LT4 groups, respectively (P = 0.01). The median TSH was 0.20 (P25-P75 0.03-1.70) mUI/L in the sLT4 group 
and 2.90 (P25-P75 0.64-9.40) mUI/L in the patients on LT4 replacement therapy (P < 0.01). The median time for patients 
on sLT4 was 6.0 (P25-P75 3.0-9.5) years, while the other group had a median time of 6.0 (P25-P75 2.0-7.0) years on LT4 
therapy. There were no differences in BMD in all the spots evaluated by DXA: lumbar spine (1.23 ± 0.17 g/cm² vs. 1.31 ± 0.14 
g/cm²; P = 0.28), femoral neck (1.09 ± 0.13 g/cm² vs. 1.13 ± 0.17 g/cm², P = 0.52), and total femur (1.06 ± 0.15 g/cm² vs. 
1.14 ± 0.16 g/cm², P = 0.28) for sLT4 and LT4 groups, respectively. All values were within the normal range, both in sLT4 
treated and LT4 replacement therapy. Of note, no patient presented low BMD (Z-score < -2). Conclusions: Long term sLT4 
therapy in young DTC patients are not associated with reduced BMD.
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Introduction: Familial non-medullary thyroid cancer (FNMTC) corresponds to 3%-6% follicular thyroid epithelium carcino-
mas and is syndromic when patients present Mendelian tumor syndromes with low preponderance of thyroid tumors, such as 
Cowden’s syndrome (CS), Gardner‘s syndrome, Carney‘s complex, and Werner‘s syndrome. Their clinical manifestations may 
vary between families. Gene mutations have already been associated with these syndromes and in 80%-85% of CS cases PTEN 
mutations have been identified. Objective: Investigate genetic alterations in a family with suspicious of syndromic FNMTC. 
Methods: The family from Piauí has 13 members diagnosed with thyroid, skin, breast, lung, gastric, oral or bone cancer. Al-
though it does not clearly fit into any of the FNMTC syndromes, the possibility of being a CS was not ruled out. Therefore, 
PTEN gene (exon and promoter) mutations were first screened by Sanger‘s sequencing from peripheral blood DNA from a 
thyroid cancer patient. Subsequently, expanded whole exome sequencing (WES) of three cancer patients was carried out using 
the SureSelectXT Human All Exon V6 + UTR Capture Library kit (Agilent) and the Illumina® NextSeq™ 500 platform. WES 
generated 3.69-4.85 Gb of data/sample with coverage greater than 30x. Results: Six PTEN polymorphisms were detected. 
Bioniformatic analysis identified 5 SNVs with high potential to be mutations in the three patients and absent in databases and 
in 18 Brazilian individuals without cancer. Only one alteration seemed to segregate with the disease and was present in two 
asymptomatic individuals. However, it was discarded because the alteration located in X chromosome could not be inherited 
from the transmitting father with lung cancer to a male asymptomatic carrier. No indels were associated to the familial disease. 
Thus, it was ruled out the possibility of being a case of syndromic FNMTC, raising the hypothesis of being a case of familial 
cancer or family grouping, characterized by the lack of inheritance pattern, high number of individuals with sporadic tumors, 
presence of various types of tumors, age of onset like sporadic cases and that may result from similar environment and/or lifes-
tyle. Conclusion: We conclude that this family could be classified as a familial case of non-hereditary cancer. However, studies 
of other regions of the genome or the use of alternatives pipelines would suggest a genetic predisposition to cancer.
